Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer.
about
Markers of resistance to anti-EGFR therapy in colorectal cancerClinical efficacy and drug resistance of anti-epidermal growth factor receptor therapy in colorectal cancerThe Insulin/IGF System in Colorectal Cancer Development and Resistance to TherapyEffectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysisFrom targets to treatments: a review of molecular targets in pancreatic neuroendocrine tumorsEvasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds.The adverse events profile of anti-IGF-1R monoclonal antibodies in cancer therapyThe insulin-like growth factor system in cancerParallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors.Mechanisms of resistance to anti-EGFR therapy in colorectal cancerSecond-line systemic therapy for metastatic colorectal cancer.Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial.A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer.Where now for anti-EGF receptor therapies in colorectal cancer?A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer.Adverse Events and Efficacy of Cixutumumab in Phase II Clinical Trials: A systematic Review and Meta-Analysis.Nanoways to overcome docetaxel resistance in prostate cancer.Engineered ubiquitin ligase PTB-U-box targets insulin/insulin-like growth factor receptor for degradation and coordinately inhibits cancer malignancyInsulin-like growth factor 1 receptor and response to anti-IGF1R antibody therapy in osteosarcoma.Phage displayed peptides/antibodies recognizing growth factors and their tyrosine kinase receptors as tools for anti-cancer therapeutics.Antibody phage display libraries: contributions to oncology.Can we unlock the potential of IGF-1R inhibition in cancer therapy?Personalized colon cancer care in 2010.A randomized, phase II study of the anti-insulin-like growth factor receptor type 1 (IGF-1R) monoclonal antibody robatumumab (SCH 717454) in patients with advanced colorectal cancer.The association of TP53 mutations with the resistance of colorectal carcinoma to the insulin-like growth factor-1 receptor inhibitor picropodophyllin.The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma.Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer.Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumorsAkt/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody.Targeting the insulin-like growth factor receptor and Src signaling network for the treatment of non-small cell lung cancer.A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK.A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancerEfficacy of anti-insulin-like growth factor I receptor monoclonal antibody cixutumumab in mesothelioma is highly correlated with insulin growth factor-I receptor sites/cell.KRAS mutant colorectal tumors: past and presentCombination of cetuximab and PP242 synergistically suppress the progression of wild-type KRAS colorectal carcinoma.Novel C6-substituted 1,3,4-oxadiazinones as potential anti-cancer agents.Targeting the insulin-like growth factor-1 receptor in human cancer.Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinomaA kinase-independent biological activity for insulin growth factor-1 receptor (IGF-1R) : implications for inhibition of the IGF-1R signal.Insulin-like growth factor: current concepts and new developments in cancer therapy.
P2860
Q24598640-2E7488F1-75C3-4DBE-AB79-2C7150AFE612Q26769958-17C0390D-69D6-4E59-BCBC-088B9B68DF5AQ26777125-917C0170-FE8D-49DC-A55F-337E2230F1FBQ26777704-63D2E546-8E3C-46F4-9C4F-D0F15C04148FQ26822011-8821CDA0-8607-451D-9386-1DC3415D6C74Q26827810-23B5E172-4150-4504-9FA1-D2F868D22827Q27000467-20B9FDDC-06F2-4072-84B9-EB47C0BB4EFCQ27013945-5FD0AB1A-F1BB-4645-8319-0E897043DC5DQ27853128-729B3E14-62D9-4B33-A4CF-6FF9C90130E6Q28074073-71D30E90-5362-49BF-A854-7E6D7999687CQ30238760-A14D2EE7-1163-4F69-9077-42C4A4DFD132Q30313824-EDB68786-DB99-4D74-935A-53B912716A39Q30316105-D8A00C62-323B-48E7-9F4B-3FFE11A078EBQ31038305-FF3A9F05-4134-4F64-8CDA-E0D87801A8EAQ33405880-A4C7CBFE-CD05-4568-ADA6-050FA871BB88Q33436873-F977DFEA-D868-411E-8F21-43DB6951B285Q33909084-7DD6B638-869B-4A07-883B-870DC77371E4Q34104101-0B4FB31E-C6BB-4373-8E37-76A6ADCBFC78Q34110523-E36AED6D-8C62-415A-A36C-8A78975CA87EQ34273411-0B270293-B4A5-4EA6-8772-D2D124FA7876Q34323991-887A3B36-B152-4703-A711-93C5624A9213Q34336988-7EB25F73-63A3-4695-92F6-73B55F93F57FQ34731381-C5268A35-7F46-41C8-83EA-ABE4E14C45ECQ35000503-B88545CE-3FA9-4638-8013-00480A2AA16AQ35030616-414FE5F4-266E-4519-8C0C-B5F9B5C3FC7FQ35209365-5701E9A6-52D8-460F-AFE9-0043968F0952Q35212113-F93B5FD5-3C89-49A3-9887-420A52578090Q35226507-D2453823-32B8-4B3D-912A-7682CA99B0A9Q35612939-B10B7141-207B-4286-A90D-9678770C18DAQ35677049-A2ADB7A7-1EEA-40B4-BF2A-214B40D787D9Q35682599-39A53DCA-C415-4D95-AC59-38384CB252F0Q35982635-16C56A9D-BB27-437F-ACC2-811F534F6087Q36019729-57467554-B571-46D2-8434-64A91DDED228Q36100844-F669C363-D85C-4581-930F-D594C047C577Q36257068-7410B535-CD79-4032-9948-CE44CC339288Q36562098-06A2A745-5429-4883-964B-4651803C8F84Q36708178-55B9B7E2-A86B-4324-BCF3-D2790BACB60CQ36859958-78984525-4DB1-459E-9F2F-BA757B16B119Q37029389-1DB5C0A2-C634-47A4-8B80-D3EA2E41B226Q37047067-80C36AF8-569C-4430-995C-2CEEB4E2063B
P2860
Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Randomized, phase II study of ...... metastatic colorectal cancer.
@ast
Randomized, phase II study of ...... metastatic colorectal cancer.
@en
type
label
Randomized, phase II study of ...... metastatic colorectal cancer.
@ast
Randomized, phase II study of ...... metastatic colorectal cancer.
@en
prefLabel
Randomized, phase II study of ...... metastatic colorectal cancer.
@ast
Randomized, phase II study of ...... metastatic colorectal cancer.
@en
P2093
P2860
P921
P356
P1476
Randomized, phase II study of ...... metastatic colorectal cancer.
@en
P2093
Aruna Dontabhaktuni
David B Solit
Diane Lauren Reidy
Efsevia Vakiani
Ellen Hollywood
Hagop Youssoufian
Joel Randolph Hecht
Jonathan Schwartz
Kumari Chandrawansa
Marwan G Fakih
P2860
P304
P356
10.1200/JCO.2010.30.4154
P407
P577
2010-08-16T00:00:00Z